🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Treating eosinophilic exacerbations of #asthma and #COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial Read open access here: thelancet.com/journals/lanre… Mona Bafadhel British Thoracic Society (BTS) Sanjay Ramakrishnan King's Faculty of Life Sciences & Medicine

Can early-life vitamin D levels influence asthma risk later on? 📢 Our study found that low vitamin D in early childhood is linked to a higher risk of eosinophilic asthma in high-risk children. 🔗 Read more: doi.org/10.1136/thorax… ThoraxBMJ UTSW Internal Medicine Chiefs Zhaozhong Zhu

Association between vitamin D status at 3 years and eosinophilic asthma in 6-year-old children with a history of severe bronchiolitis George Doumat thorax.bmj.com/content/early/…

ERR: A review presenting our current understanding of the role of vascularity in the pathogenesis of interstitial lung diseases, emphasising its potential contribution to the exacerbation of fibrosis and its therapeutic implications. bit.ly/3NLn4Rg

1/2 New pub in ATS Blue Journal We challenge the paradigm that all emphysema results from small airway disease. We show that most new emphysema arises from areas of high Mechanically Affected Lung (MAL) and in substantially higher proportion than areas of small airways disease.

Critical Care medicine clinical practice updates 1. Insufficient evidence to recommend benzos for anxiety 2. Use dexmedetomidine over propofol for light sedation 3. Unable to recommend antipsychotics for delirium 4. Suggest enhanced mobilization over usual care 5. Use

ERJ Open Research: Young COPD patients suffer from significant disease burden, and display an altered biomarker and disease progression profile reflected by an accelerated risk of lung function decline bit.ly/4ecdYbF

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials - The Lancet Respiratory Medicine thelancet.com/journals/lanre… The Lung Institute at Baylor Medicine BCM PCCSM section

🔥 🔥 🔥 Hot of the press: Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis buff.ly/CGXv34s

Here are some top line takeaways on #foodorder from #CCOM2025 Alpana Shukla 👉 Eat carbs last. ⬇️insulin, ⬇️glucose peak, ⬇️ghrelin 1/

A new review discusses challenges and pitfalls in the diagnosis and management of chronic cough that is unexplained after a complete evaluation or that is refractory to treatment for identified causes. Read the Review Article “Unexplained or Refractory Chronic Cough in Adults”

Just out 🔥🔥 Hydrocortisone in severe community acquired pneumonia - results from REMAP-CAP 7 day fixed dose hydrocortisone - Stopped for futility 15% mortality with HC vs 9.8% with standard care. Unlikely that hydrocortisone substantially reduce mortality in CAP.

In the ASPEN phase 3 trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo. Full trial results: nej.md/4lBHwUr Editorial:

Scientists led by Dr Jonathan Koff found that personalized phage therapy was associated with decreased sputum P. aeruginosa and improved lung function, which may reflect the effects of phage-driven evolved trade-offs. 🫁 Nature Medicine | go.nature.com/3ELQIVR

A new COPD diagnostic schema that includes chest imaging, respiratory symptoms, and spirometry identified more high-risk individuals and excluded low-risk ones. #ATS2025 ja.ma/4dp9i30

Newly proposed diagnostic schema for COPD using major and minor criteria classifies individuals as having this disease beyond airflow limitation and identifies individuals at increased risk for poor outcomes. doi:10.1001/jama.2025.7358 JAMA